Welcome to our dedicated page for Enovis SEC filings (Ticker: ENOV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Enovis Corporation filings document the formal disclosures of a public medical technology company with Reconstructive and Prevention & Recovery operations. Recent Form 8-K reports cover quarterly and annual results, furnished earnings releases, conference presentation materials and Regulation FD disclosures tied to management presentations.
The filing record also includes proxy materials for annual meeting governance, board and executive compensation matters, executive transition disclosures, and material financing agreements. Enovis filings describe credit facilities, leverage covenants, guarantor arrangements, senior unsecured convertible notes references, financial condition, segment performance and related risk and governance subjects.
Enovis director Angela S. Lalor reported acquiring 742 shares of Enovis Corp (ENOV) on 09/30/2025 at a reported price of $0.00, increasing her direct beneficial ownership to 21,295 shares. The Form 4 shows the filing was signed by attorney-in-fact Brian P. Hanigan on 10/01/2025. The filing identifies Lalor as a director and indicates this is a single-person Form 4 filing. No derivative transactions or additional details are reported.
Damien McDonald, listed as Chief Executive Officer and Director of Enovis Corporation (ENOV), purchased 6,457 shares of Enovis common stock on 09/11/2025. The reported weighted-average price per share was $30.97, with transaction prices ranging from $30.73 to $31.16. After the purchase, the reporting person beneficially owned 102,753 shares. The Form 4 was signed on behalf of Mr. McDonald by attorney-in-fact Brian P. Hanigan.
Insider purchase by Enovis executive: Tandy Bradley J, SVP and Chief Legal Officer of Enovis Corporation (ENOV), reported purchasing 3,200 shares of Enovis common stock on 08/22/2025 at a price of $31.41 per share. After the transaction, Mr. Bradley beneficially owned 43,515 shares. The Form 4 was signed via attorney-in-fact on 08/25/2025.
Enovis insider purchase disclosed on Form 4. Philip Benjamin Berry, SVP and Chief Financial Officer, purchased 2,500 shares of Enovis Corporation (ticker ENOV) on 08/20/2025 at a price of $29.71 per share. After the transaction, Mr. Berry beneficially owned 116,729 shares. The Form 4 was filed as a single reporting person filing and was signed by attorney-in-fact Brian P. Hanigan on 08/20/2025.
The filing discloses that multiple American Century entities and the Stowers Institute report material beneficial ownership in Enovis Corporation common stock. American Century Investment Management, Inc., American Century Companies, Inc. and Stowers Institute each report beneficial ownership of 4,737,327 shares, representing 8.3% of the class, with sole voting power of 4,580,116 shares and sole dispositive power of 4,737,327 shares as shown on their cover pages. American Century Capital Portfolios, Inc. reports ownership of 3,060,000 shares, representing 5.4% of the class, with sole voting and dispositive power.
The filing states these securities are held in the ordinary course of business and were not acquired to change or influence control of the issuer. An exhibit shows that the reporting persons consented to a joint filing, and signatures certify the accuracy of the statement.
Davenport & Co LLC reported beneficial ownership of 2,756,270 shares of Enovis common stock, representing 4.83% of the class. The filer discloses sole voting power over 2,730,225 shares and sole dispositive power over 2,756,145 shares. The statement is filed on Schedule 13G as an investment adviser and indicates the holding is 5% or less of the class.
This filing also contains a certification that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Enovis Corp. (ENOV) – Form 4 filing dated 08/07/2025
Group President, Recon, Louis Vogt reported one transaction on 08/05/2025. The Form 4 shows an F-code entry—shares withheld by the company to cover tax obligations arising from the net settlement of previously granted restricted stock units.
- Securities withheld: 460 common shares
- Price applied for withholding: $26.46 per share
- Post-transaction direct holdings: 36,385 common shares
Enovis Corporation (ENOV) filed a Form 4 disclosing an insider withholding transaction by reporting person John Kleckner, identified as the company's Principal Accounting Officer. On 08/05/2025, 173 shares of Enovis common stock were withheld in connection with the net settlement of restricted stock units to satisfy tax withholding obligations at a per‑share amount of $26.46. The filing explicitly notes this action does not represent a sale by the reporting person.
After the withholding, Mr. Kleckner beneficially owned 9,834 shares of Enovis common stock, held directly. The Form 4 was signed by attorney‑in‑fact Brian P. Hanigan on 08/07/2025. The filing includes the reporting person’s address in Wilmington, DE.
Ross Terry D, Group President, P&R, of Enovis Corporation (ENOV) reported a Form 4 transaction dated 08/05/2025. The filing shows 325 common shares were withheld by the company to satisfy tax withholding in connection with the net settlement of restricted stock units, at a per-share price of $26.46. Following this withholding, the reporting person is shown as beneficially owning 35,789 shares. The form was filed by one reporting person and signed by attorney-in-fact Brian P. Hanigan on 08/07/2025.
The filing explicitly states the withheld shares do not represent a sale by the reporting person.
Enovis (ENOV) Q2 2025 10-Q highlights: Net sales grew 7.5% YoY to $564.5 million, led by Reconstructive (+10.7%) and steady Prevention & Recovery (+4.6%). Gross profit rose 15.9% to $334.7 million, lifting gross margin to 59.3% (vs. 55.0%). Operating loss narrowed to $16.8 million from $44.2 million on flat SG&A, but a $10.0 million royalty-buyout charge, higher R&D and intangible amortization kept GAAP earnings negative.
The company reported a net loss attributable to Enovis of $36.7 million (-$0.64 per share) versus $18.6 million (-$0.34) last year, driven by a $10.8 million tax expense versus an $8.9 million benefit in the prior period and hedging losses. Adjusted EBITDA improved 7.7% to $97.1 million. Operating cash flow swung to an inflow of $46.2 million (-$28.4 million LY) as working-capital efficiencies offset higher inventory. Cash ended at $44.1 million; total debt increased to $1.39 billion, lifting net debt by $84 million since year-end.
Balance-sheet expansion reflects completion of seven small acquisitions ($35 million consideration) and Lima integration costs. Inventories climbed 15% YTD, while goodwill and intangibles rose after bolt-on deals. Management remains in compliance with leverage covenants (senior secured leverage ≤3.5×) and has $325 million undrawn on its $900 million revolver.